Combination of Yondelis (ET-743) and oxaliplatin in experimental ovarian cancer.

被引：0
|
作者：
Erba, E
Colombo, T
Ubezio, P
Ferrarese, L
Matera, G
Falcioni, C
Faircloth, G
Jimeno, J
D'Incalci, M
机构：
[1] IM Mario Negri, Milan, Italy
[2] PharmaMar R&D, Boston, MA USA
[3] PharmaMar R&D, Madrid, Spain
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6264S / 6264S
页数：1
相关论文
共 50 条
  • [31] In vitro cytotoxicity of Ecteinascidin 743 (ET-743) against human hemopoietic progenitors and cancer cells
    Ghielmini, M
    Colli, E
    Erba, E
    Bergamoschi, D
    Jimeno, J
    Faircloth, G
    Sessa, C
    ANNALS OF ONCOLOGY, 1998, 9 : 139 - 139
  • [32] Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743)
    E Erba
    D Bergamaschi
    L Bassano
    S Ronzoni
    G Di Liberti
    I Muradore
    S Vignati
    G Faircloth
    J Jimeno
    M D'Incalci
    British Journal of Cancer, 2000, 82 : 1732 - 1739
  • [33] Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53
    Moneo, Victoria
    Serelde, Beatriz G.
    Fominaya, Jess
    Leal, Juan F. M.
    Blanco-Aparicio, Carmen
    Romero, Lourdes
    Sanchez-Beato, Margarita
    Cigudosa, Juan C.
    Tercero, Juan C.
    Piris, Miguel A.
    Jimeno, Jose
    Carnero, Amancio
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 100 (02) : 339 - 348
  • [34] Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug:: Yondelis™ (ET-743)
    Gómez, SG
    Bueren, JA
    Faircloth, G
    Albella, B
    TOXICOLOGY IN VITRO, 2003, 17 (5-6) : 671 - 674
  • [35] Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action
    Martinez-Serra, Jordi
    Maffiotte, Elena
    Martin, Javier
    Bex, Teresa
    Navarro-Palou, Maria
    Ros, Teresa
    Plazas, Joana M.
    Voegler, Oliver
    Gutierrez, Antonio
    Carlos Amat, Juan
    Ramos, Rafael
    Saus, Carlos
    Gines, Jordi
    Alemany, Regina
    Diaz, Matias
    Besalduch, Joan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 658 (2-3) : 57 - 64
  • [36] The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71
    Manara, MC
    Perdichizzi, S
    Serra, M
    Pierini, R
    Benini, S
    Hattinger, CM
    Astolfi, A
    Bagnati, R
    D'Incalci, M
    Picci, P
    Scotlandi, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (06) : 1605 - 1616
  • [37] Experience of the use of trabectedin (ET-743, Yondelis™) in 21 patients with pre-treated advanced sarcoma from a single centre
    Roylance, R.
    Seddon, B.
    McTiernan, A.
    Sykes, K.
    Daniels, S.
    Whelan, J.
    CLINICAL ONCOLOGY, 2007, 19 (08) : 572 - 576
  • [38] Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas Report on Five Patients and a Review of the Literature
    Amant, Frederic
    Coosemans, An
    Renard, Vincent
    Everaert, Els
    Vergote, Ignace
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (02) : 245 - 248
  • [39] In vitro (IVT) changes in the Gene Expression Profiling (GEP) induced by Ecteinascidin-743 (Yondelis, ET-743) in a panel of samples from sarcoma (SAR) patients (pts).
    Sanchez-Beato, M
    Moneo, MV
    Martinez, N
    Fernandez, I
    Camero, A
    Piris, MA
    Jimeno, J
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6263S - 6264S
  • [40] Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype
    Beumer, Jan-Hendrik
    Buckle, Tessa
    Ouwehand, Mariet
    Franke, Niels E. F.
    Lopez-Lazaro, Luis
    Schellens, Jan H. M.
    Beijnen, Jos H.
    van Tellingen, Olaf
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (01) : 1 - 7
12345